medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2018, Number 5

<< Back Next >>

Rev Mex Urol 2018; 78 (5)

Frequency of allelic variants of the TMPRSS2 gene in a prostate cancer-free Southwestern Colombian population

García-Perdomo HA, Zamora-Segura BD, Sánchez A

Language: English
References: 21
Page: 354-358
PDF size: 310.36 Kb.


ABSTRACT

Objective: To describe the frequency of the TMPRSS2 gene and its variants in a prostate cancer-free Southwestern Colombian population.
Materials and Methods: An observational study was conducted that included cancerfree persons, regardless of age, from Southwestern Colombia. Blood samples were drawn from the patients for DNA extraction. Blood drops were collected and dried on filters and immersed in phosphate buffer, utilizing the DNeasy kit. The preparation process was carried out using the TruSeq Exome Library Prep® kit and the resulting libraries were normalized with the TruSeq Rapid Exome® kit. The commercial kits were provided by Illumina®. We sequenced the full exome and identified the variants associated with the TMPRSS2 gene. Descriptive statistics were employed for the data analysis.
Results: The study population was made up of 162 persons from whom 7,315,466 sequence data were obtained. The TMPRSS2 gene was found in 414 data (4.3%). The most common SNP was rs140530035 (32.1%) and the most relevant SNP sequenced was rs12329760 (10.6%).
Conclusion: TMPRSS2 was not frequent in the population studied. The most important polymorphism associated with the TMPRSS2 gene was rs12329760.


REFERENCES

  1. Bray F, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008 GLOBOCAN. Int J Cancer 2013;132(5):1133-45. DOI: 10.1002/ijc.27711

  2. Valencia O, et al. Incidence and Prevalence of Cancer in Colombia: The Methodology Used Matters. J Glob Oncol 2018;(4):1-7. DOI: 10.1200/JGO.17.00008

  3. Bashir MN. Epidemiology of Prostate Cancer. Asian Pacific J Cancer Prev 2015;16(13):5137-41.

  4. Rebbeck TR. Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol 2016;27(1):3- 10. DOI: 10.1016/j.semradonc.2016.08.002

  5. Parkin DM, et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer 2010;127:2918-27. DOI: 10.1002/ijc.25517

  6. Poveda-Matiz JL, et al. Evolución de la mortalidad por cáncer de próstata en Colombia: estudio ecológico. Urol Colomb 2014;23(1):3-10. Dirección URL: .

  7. Antczak A, et al. The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men. Eur J Cancer Prev 2015;24(2):122-7. DOI: 10.1097/CEJ.0000000000000079

  8. Antalis T, et al. Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci 2011;99:1-50. DOI: 10.1016/B978-0-12-385504-6.00001-4

  9. Fernández-Serra A, et al. Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR. Biomed Res Int 2013;2013:465179. DOI: 10.1155/2013/465179

  10. Wang J, et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66(17):8347-51. DOI: 10.1158/0008- 5472.CAN-06-1966

  11. Whirl-Carrillo M, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414-7. DOI: 10.1038/clpt.2012.96

  12. Landrum M, et al. ClinVar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res 2018;46(D1):D1062-D1067. DOI: 10.1093/nar/gkx1153

  13. Sherry S, et al. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res 2001;29(1):308-11.

  14. Blee AM, et al. TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53 -mutated prostate cancer. Clin Cancer Res 2018;24(18):4551- 4565. DOI: 10.1158/1078-0432.CCR-18-0653

  15. Knuuttila M, et al. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer. Endocr Relat Cancer 2018;25(9):807-19. DOI: 10.1530/ERC-18-0148

  16. Fernández-Serra A, et al. Cáncer de próstata: la revolución de los genes de fusión. Actas Urol Esp 2011;35(7):420-8. Dirección URL: .

  17. Tomlins SA, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. Neoplasia 2008;10(2):177- 88. Dirección URL: .

  18. Bismar TA, et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 2011;107(3):477–85. DOI: 10.1111/j.1464- 410X.2010.09470.x

  19. Hsu F-C, et al. Comparison of two methods for estimating absolute risk of prostate cancer based on single nucleotide polymorphisms and family history. Cancer Epidemiol Biomarkers Prev 2010;19(4):1083-8. DOI: 10.1158/1055- 9965.EPI-09-1176

  20. Karczewski KJ, et al. The ExAC browser: displaying reference data information from over 60 000 exomes. Nucleic Acids Res 2017;45(D1):D840-5. DOI: 10.1093/nar/gkw971

  21. Lek M, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016;536(7616):285-91. DOI: 10.1038/nature19057




2020     |     www.medigraphic.com